Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer
JAMA Network Open · 15.06.2026 · 9 (6) · e2616154
DOI: 10.1001/jamanetworkopen.2026.16154 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Network Open, online erschienen am 15.06.2026. Verfasst von Xin Wang und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Tumor Multimodality Treatment, West China Hospital, Sichuan University, Sichuan, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Chemoradiotherapy, Adjuvant, Gastrectomy, Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Despite advances in D2 gastrectomy (ie, gastrectomy with D2 lymphadenectomy) and adjuvant chemotherapy, the value of adding postoperative radiotherapy (RT) to adjuvant chemotherapy after D2 gastrectomy remains a topic of ongoing debate.
Objective
To assess whether the addition of RT to the S-1 plus oxaliplatin (SOX) chemotherapy regimen increases disease-free survival (DFS) in patients with T4 or node-positive gastric cancer after D2 gastrectomy. Design, Setting, and Participants This open-label, phase 3 randomized clinical trial was conducted between December 1, 2012, and August 30, 2022, at 5 large tertiary hospitals in China. Eligible patients were aged 18 to 70 years with gastric adenocarcinoma who underwent R0 resection with D2 lymphadenectomy, had pathologic stage T4 or node-positive disease, and had no evidence of metastasis (M0). Intention-to-treat statistical analyses were conducted from January 14 to March 31, 2025.
Interventions
Participants were assigned 1:1 to receive concurrent chemoradiotherapy (SOX RT) or chemotherapy alone (SOX). The SOX RT group received 1 cycle of induction SOX, followed by RT (50.4 Gy in 28 fractions) with concurrent S-1 (50 mg twice daily), and then 3 cycles of SOX. The SOX group received 6 cycles of SOX (S-1 30-40 mg/m 2 twice daily on days 1-14; oxaliplatin 130 mg/m 2 on day 1, every 3 weeks). Main Outcomes and Measures The primary end point was 3-year DFS. Secondary end points included overall survival (OS) and adverse events.
Results
A total of 620 patients were randomly assigned to the SOX group (n = 311) or SOX RT group (n = 309). Patients had a median (IQR) age of 55 (47-62) years and included 401 males (64.7%). Overall, 274 patients (44.2%) had T4 disease, and 590 (95.2%) had node-positive disease. In the primary analysis for the prespecified 3-year DFS end point, there was no evidence of a between-group difference in DFS (SOX RT vs SOX: HR, 0.98; 95% CI, 0.73-1.33). Similarly, there was no evidence of a between-group difference in OS (HR, 0.86; 95% CI, 0.60-1.23). The Kaplan-Meier–estimated 3-year DFS rates were 70.5% in the SOX RT group and 69.3% in the SOX group (log-rank P = .93), and the corresponding 3-year OS rates were 80.8% and 78.4%, respectively (log-rank P = .41). At 5 years, the DFS rates were 60.0% and 57.3% (log-rank P = .76) and the corresponding OS rates were 73.7% and 71.4% (log-rank P = .55) in the SOX RT and SOX groups, respectively. Treatment-related adverse events were similar between groups. Conclusions and Relevance In this randomized clinical trial of patients with T4 or node-positive gastric cancer who underwent D2 gastrectomy, SOX RT did not significantly improve DFS or OS. Accordingly, among patients with D2-resected gastric cancer, the findings do not support routine addition of adjuvant chemoradiotherapy to chemotherapy. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR-TRC-12002919
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Abdominal Tumor Multimodality Treatment, West China Hospital, Sichuan University, Sichuan, China.
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Sichuan, China.
- Department of Radiation Oncology, West China Hospital, Sichuan University, Sichuan, China.
- Department of Abdominal Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
- Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China.
- Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
Zitieren
APA
Wang, X., Yan, O., Zhou, J., Wen, F., Shen, Y., Li, Z., Li, Q., Wang, W., Cai, X., Tan, S., Wang, Z., Qiao, Q., Cao, D., Qiu, M., Liu, J., Gou, H., Liu, M., Yi, C., Yang, Y., …, & Bi, F. (2026). Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer. JAMA Network Open, 9(6), e2616154. https://doi.org/10.1001/jamanetworkopen.2026.16154
Vancouver
Wang X, Yan O, Zhou J, Wen F, Shen Y, Li Z, et al. Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer. JAMA Network Open. 2026;9(6):e2616154. doi:10.1001/jamanetworkopen.2026.16154
BibTeX
@article{Wang2026,
author = {Wang, Xin and Yan, Ouying and Zhou, Jitao and Wen, Feng and Shen, Yali and Li, Zhiping and Li, Qiu and Wang, Wenling and Cai, Xiaohong and Tan, Shisheng and Wang, Zi and Qiao, Qing and Cao, Dan and Qiu, Meng and Liu, Jiyan and Gou, Hongfeng and Liu, Ming and Yi, Cheng and Yang, Yu and Zhu, Qing and Luo, Deyun and Zhao, Yaqin and Chen, Ye and Wang, Shang and Wang, Qiaoli and Cheng, Ke and Ren, Min and Liu, Xin and Xu, Feng and Bi, Feng},
title = {Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {6},
pages = {e2616154},
doi = {10.1001/jamanetworkopen.2026.16154}
}
EUVIMED